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Abstract
T-cell prolymphocytic leukemia (T-PLL) is a rare mature T-cell lymphoma. The diagnosis of T-PLL is made based on the 
criteria proposed in 2019 by the T-PLL International Study Group (TPLL-ISG). T-PLL may be diagnosed in an ‘active’ or 
an ‘inactive’ form. While T-PLL is most often characterized by an aggressive clinical course, approximately 20–30% of 
patients may have a stable or slowly progressive disease in the initial period. Only the active form requires treatment. 
The treatment initiation criteria were defined in the consensus proposed by the TPLL-ISG. Data on the effectiveness of 
various therapeutic approaches comes from small, non-randomized studies. No drug is approved for the treatment of 
T-PLL. The standard of care in the first line of treatment is intravenous alemtuzumab. Consolidation therapy in eligible 
patients consists of allogeneic hematopoietic stem cell transplantation, preferably after TBI-based conditioning. In the 
remaining patients, neither maintenance nor consolidation treatment is recommended. There is no standard therapy for 
the relapse, although, based on genome studies, many drugs may be potentially effective, including histone deacetylase 
inhibitors and BCL2 inhibitors.
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Introduction
T-cell prolymphocytic leukemia is a rare lymphoma derived 
from mature peripheral T lymphocytes [1]. It was distin-
guished from chronic lymphocytic leukemia for the first 
time in 1973 based on the clinical picture, the morphology 
of the tumor cells, and the poor prognosis [2]. The new 
entity also included T-cell chronic lymphocytic leukemia, 
which had been distinguished in previous classifications 
[3, 4]. Its incidence is estimated at around 0.6–2 new 
cases per 1,000,000 per year [5, 6], which is about 2% of 
all chronic leukemias. In Poland, no more than 30 cases 
are diagnosed annually.
T-PLL occurs mainly in older people, with a median 
age at diagnosis of 60+. Men are affected twice as often 
as women. The clinical course is usually aggressive. In ap-
proximately 20–30% of patients, T-PLL may develop slowly 
in the initial stage [7]. The duration of the ‘chronic’ phase 
of the disease varies. Despite the initial ‘benign’ course, 
almost all patients are expected to progress and die due 
to the disease.
Pathogenesis
Genetic changes observed in T-PLL include translocations 
of proto-oncogenes to the vicinity of constitutively active 
TCR receptor chain genes (alpha and delta) on chromo-
some 14q11.2, e.g. t(14; 14)(q11; q32) or t(X; 14)(q28; 
q11) or inv(14)(q11; q32). The consequence of the result-
ing genetic lesions is the activation of TCL1 (14q32) or 
MTCP1 (Xq28) genes. TCL1 gene encodes a TCL1 protein 
that in vitro modulates the activity of AKT serine-threonine 
kinases involved in signaling from the TCR receptor. How-
ever, these genetic lesions are not sufficient for leukemia 
transformation. Secondary cytogenetic changes include 
both amplifications and deletions, including 11q and ATM 
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gene as well as chromosomes 8 and 17. The accumulation 
of various mutations results in complex karyotype observed 
in the majority of patients [8]. It is generally accepted that 
TCL1 activation and impaired ATM activity play a key role 
in the pathogenesis of T-PLL, and the phenotype of T-PLL 
cells can be described as TCL1up/ATMdef [9, 10].
Unlike in other neoplasms, mutations in the TP53 gene 
are rarely found in T-PLL. Nevertheless, p53 activation is 
hampered by ATM deficiency, and in consequence normal, 
deacetylated p53 remains bound to MDM2 (mouse double 
minute 2), TP53 inhibitor [9].
Mutations in genes responsible for histone modifica-
tions, such as KMT2C, KMT2D, KMT5A, and EZH2 are often 
observed in T-PLL [9, 11]. DNA repair is further impaired by 
the altered expression of genes encoding for components 
of epigenetic regulation [11].
Chromosome 8 trisomy and iso8q are observed in 
approximately two in every three patients; in some cas-
es, these lesions may be related to MYC overexpression 
[6, 12, 13]. JAK and STAT activating mutations are ob-
served in more than 60% of patients. The most common 
mutations are single nucleotide variants (SNVs) of JAK3, 
JAK1, and STAT5B [11, 12, 14]. No mutations are observed 
in BCL2 gene family [9].
HTLV-1 is not involved in oncogenesis in patients with 
T-PLL [6].
Clinical presentation
T-PLL is characterized by rapidly increasing lymphocytosis, 
most often exceeding 100 ×109/L. Splenomegaly and 
hepatomegaly are present at diagnosis in the majority of 
patients. Lymphadenopathy, skin lesions (skin nodules, 
rash, rarely erythroderma), peripheral edema, including 
conjunctival edema and periorbital edema, and pleural and 
peritoneal effusions are observed in some cases. Central 
nervous system involvement is possible, although this is 
rarely observed. Patients often complain of B symptoms 
[1, 6, 15, 16].
T-PLL diagnostic criteria
Diagnostic tests
In 2019, the T-PLL International Study Group (TPLL-ISG) 
published diagnostic recommendations for T-PLL [8]. Ac-
cording to these, the diagnosis of T-PLL includes cytological 
evaluation of peripheral blood smear, immunophenotyping, 
and genetic testing.
The diagnosis of T-PLL is based on the detection of one 
three morphological variants of clonal prolymphocytes in 
the peripheral blood or bone marrow. Most often (75% of 
cases), T-PLL cells are medium-sized, with a high nuclear-cy-
toplasmic ratio, moderately condensed chromatin, single, 
clearly visible nucleolus, slightly basophilic cytoplasm, and 
cytoplasmic protrusions. In 20% of cases, T-PLL cells are 
small, with condensed chromatin; the nucleolus is invisible 
by light microscopy. In 5% of cases, the nucleus resembles 
the shape of the brain (cerebriform variant). There are no 
differences in clinical course between the morphological 
variants. Despite the characteristic features, T-PLL can-
not be diagnosed solely on the basis of cell morphology.
Flow cytometry is one of the basic diagnostic tools used 
to diagnose T-PLL and differentiate it from other neoplasms 
originating from T cells. T-PLL prolymphocytes express anti-
gens typical for mature T cells, such as CD3, CD5, and CD7, 
as well as the cytoplasmic TCL1. No expression of CD1a 
is detected [9]. T-PLL cells can be both CD4+ (~60%) and 
CD8+ (~15%), or they may express both antigens simulta-
neously (~25%) [8]. CD52 is also expressed, and high den-
sity of this antigen explains the high sensitivity of T-PLL to 
alemtuzumab. Antigens such as CD25, CD38, and HLA-DR 
are expressed with different frequencies, and markers of 
cytotoxic granules, e.g. TIA-1, are always negative, even in 
CD8+ prolymphocytes. The phenotype of prolymphocytes 
may change during the course of the disease and treat-
ment [6, 15, 16].
Genetic tests include TCR rearrangement (TRB, TRG) 
assessment to evaluate cell clonality as well as karyotype 
and fluorescent in situ hybridization (FISH). Clonal TCR re-
arrangement evaluation is obligatory in all patients, while 
other tests are optional and recommended only in specif-
ic cases. Approximately 70–80% of patients have a com-
plex karyotype with repeated cytogenetic lesions, such as 
inv(14)(q11q32), t(14;14)(q11;q32), t(X;14)(q28;q11), 
missense deletions or mutations within 11q23, idic(8)p11, 
t(8;8)(p11-12; q12), 8q trisomy, and del(12p) [8]. These 
lesions are described in detail in the ‘Pathogenesis’ sec-
tion above.
Bone marrow examination is not necessary for diagno-
sis. Indications for bone marrow examination, as well as 
for other affected organs biopsy, depend on the clinical 
situation. In patients from endemic areas, it is necessary 
to test for HTLV1 infection with serological or polymerase 
chain reaction (PCR)-based methods.
The diagnosis of T-PLL is made based on major and 
minor criteria (Table I). The diagnosis of T-PLL is estab-
lished when all major criteria, or the first two major criteria 
and at least one minor criterion, are met. In patients with 
no TCL1A, TCL1B, or MTCP1 rearrangement or overexpres-
sion, TCL1-family negative T-PLL is diagnosed.
Differential diagnosis of T-PLL includes other T-cell 
lymphomas in leukemic phase, including: T-cell acute lym-
phoblastic leukemia, characterized by the expression of 
TdT and CD1a, peripheral T-cell lymphoma, not express-
ing cyTLC1–, T-cell large granular lymphocytic leukemia 
(T-LGL) CD8+, CD57+, CD16+, Sézary syndrome CD7–, CD4+, 
CD25+, and adult T-cell lymphocytic leukemia (ATLL) CD4+, 
CD25+, HTLV1+.
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Prognostic factors
So far, no prognostic index has been developed for patients 
with T-PLL, mostly due to the rarity of the disease. In mul-
tivariate analysis of 119 patients treated in 1990–2016 
published by Jain et al. [17], the following factors negatively 
affected overall survival (OS): pleural effusion (HR =2.08; 
95% CI: 1.11–3.9), high LDH activity (≥1.668 IU/L) (HR 
=2.5; 95% CI: 1.20–4.24), and low hemoglobin concentra-
tion (<9.3 g/dL) (HR =0.33; 95% CI: 0.14–0.75).
In the study by Hu et al. involving 97 patients, complex 
karyotype was associated with a shorter OS compared to 
the normal karyotype. The authors were not able to demon-
strate the prognostic significance of any specific cytoge-
netic lesions for OS. However, the presence of at least five 
cytogenetic aberrations was a negative prognostic factor 
for survival [18]. Similarly, the presence of the JAK3 mu-
tation, as shown by Stengel et al. [19], and high TCL1 ex-
pression, as shown by Herling et al, are associated with 
a poorer prognosis [13].
Indications for treatment initiation;  
pre-treatment evaluation
As already mentioned, T-cell prolymphocytic leukemia may 
initially have a slow course in some patients. There is no data 
indicating that initiation of treatment at this stage improves 
long-term outcomes. Therefore, in accordance with the rec-
ommendations of the TPLL-ISG, patients do not require any 
treatment at this stage. Treatment should only be initiated 
in patients who have active T-PLL, which is defined as having 
at least one of the treatment initiation criteria presented 
in Table II. Close monitoring is recommended in patients 
with inactive T-PLL. This should include a monthly physical 
examination and complete blood count. The TPLL-ISG 
treatment initiation criteria are set out in Table II [8]. These 
recommendations also cover relapsed T-PLL.
Before treatment initiation, all patients require evalu-
ation according to Cumulative Illness Rating Scale (CIRS), 
Eastern Cooperative Oncology Group (ECOG) performance 
status, and computed tomography of the neck, chest, ab-
domen, and pelvis. PET/CT examination is not currently 
recommended, although there are reports suggesting the 
usefulness of this examination in these patients [20]. As 
is the case with other lymphomas, it is necessary to de-
termine the activity of lactate dehydrogenase (LDH) and 
the virological status of the patient (HBV, HCV, HIV, HSV).
Therapy
Due to the very low incidence of T-PLL, data on treatment 
efficacy comes from small, non-randomized studies. 
Evaluating treatment efficacy is further complicated by 
the different diagnostic and response criteria used by 
different authors [8]. However, we know for certain that 
T-cell prolymphocytic leukemia is resistant to conventional 
chemotherapy [6, 21]. For these reasons, other treatments 
for T-PLL have been sought.
The first improvement in the treatment outcome was 
associated with the use of purine nucleoside analogues. 
The response rate in pentostatin-treated patients was 45%, 
Table I. Diagnostic criteria for T-cell prolymphocytic leukemia (T-
-PLL) according to T-PLL International Study Group (TPLL-ISG) [8]
Major criteria
1. >5 ×109/L cells with the T-PLL phenotype in the peripheral 
blood or bone marrow
2. T-cell clonality (determined by TRB/TRG PCR or flow cyto-
metry)
3. Abnormalities of 14q32 or Xq28 OR expression  
of TCL1A/B or MTCP1
Minor criteria
1. Chromosome 11 abnormalities (11q22.3;ATM) 
2. Chromosome 8 abnormalities: idic(8)(p11), t(8;8), trisomy 8q
3. Chromosome 5, 12, 13, and 22 abnormalities or a com-
plex karyotype
4. Involvement of T-PLL specific site (e.g. splenomegaly, 
effusions)
TRB — T-cell receptor β; TRG — T-cell receptor γ; PCR — polymerase chain reaction
Table II. T-cell Prolymphocytic Leukemia International Study 
Group (TPLL-ISG) treatment initiation criteria (at least 1 criterion 
must be met to initiate the treatment) [8]
Symptoms related 
to the disease
ECOG performance status ≥2
Unintentional weight loss >10% within 
6 months
Drenching night sweats, without evi-
dence of infection
Fever >38°, without evidence of infection
Symptomatic bone 
marrow failure
Anemia (Hb <10 g/dL)





>50% in 2 months; doubling in diame-
ter <6 months
Symptomatic enlargement of the 
lymph nodes, spleen, or liver
Increasing lympho-
cytosis
If >30 × 109/L: >50% in 2 months
Lymphocyte doubling time in less than 
6 months
Extranodal disease Organ infiltration
Pleural or peritoneal effusion
Central nervous system involvement
ECOG — Eastern Cooperative Oncology Group; Hb — hemoglobin; PLT — platelets
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while the complete remission rate was 9%, with a medi-
an progression-free survival (PFS) of 6 months and OS of 
9 months [22]. Another breakthrough was related to the use 
of alemtuzumab. Dearden et al. [23] showed that admin-
istration of alemtuzumab in a group of previously treated 
patients induced response in 76%, including 60% of com-
plete remission and 16% of partial remission. Unfortunate-
ly, the combined use of alemtuzumab and pentostatin did 
not translate into outcome improvement as compared to 
alemtuzumab monotherapy [24].
First-line treatment
Alemtuzumab, a humanized anti-CD52 monoclonal antibody, 
is currently recommended as first-line treatment for T-PLL. 
As with other monoclonal antibodies, the mechanism of 
action is based on the induction of antibody-dependent 
cellular cytotoxicity, complement-dependent cytotoxicity, 
and direct induction of cell death [25]. Alemtuzumab is 
used at the standard dose, i.e. 30 mg three times a week 
intravenously over 10–12 weeks. Alemtuzumab induces 
response in 91% of patients, including 81% of complete 
remission (CR). There are no recommendations regarding 
treatment prephase in patients with high baseline tumor 
mass. Therapeutic leukapheresis should be considered. 
A study comparing the efficacy of intravenous and subcu-
taneous alemtuzumab was prematurely discontinued due 
to a very low response rate in the subcutaneous arm (33%) 
and a high percentage of deaths in this patient group [26]. 
It seems that this phenomenon is caused by the slower 
achievement of the desired antibody concentration in serum 
after subcutaneous administration. Lack of response after 
subcutaneous administration of the antibody may be also 
caused by the formation of neutralizing antibodies against 
alemtuzumab [27, 28]. Median progression-free survival 
in patients treated with alemtuzumab ranges from 7–12 
months, as summarized in the study by Braun et al. [29].
The use of alemtuzumab in combination with chemo-
therapy does not improve the effectiveness of the treat-
ment compared to intravenous alemtuzumab monothera-
py. A German group analyzed the effectiveness of the two 
protocols FMC+A and FMCA+A in phase II clinical trials [30, 
31]. For the FMC+A protocol, the authors initially used four 
cycles of FMC [fludarabine 25 mg/m2 intravenous (i.v.) on 
days 1–3, mitoxantrone 8 mg/m2 i.v. on day 1, cyclophos-
phamide 200 mg/m2 on days 1–3], followed by treatment 
consolidation with alemtuzumab i.v. for up to 12 weeks. 
Response rate after FMC was 68%, and the addition of 
alemtuzumab increased this to 92%. Median OS of pa-
tients treated with FMC-A was 17.1 months, and progres-
sion-free survival was 11.9 months. The most frequently 
observed adverse events included hematological compli-
cations and CMV infection reactivation. In the FMCA+A pro-
tocol, subcutaneous alemtuzumab was administered from 
the very beginning of the treatment [10 mg subcutaneous 
(s.c.) days 1–3 in cycles 1–2, 30 mg s.c. days 1–3 in cy-
cles 3–4 in the absence of CR after two cycles] together 
with FMC at the following doses: fludarabine 20 mg/m2 i.v. 
on days 1–3, mitoxantrone 6 mg/m2 i.v. on day 1, cyclo-
phosphamide 200 mg/m2 on days 1–3. Maintenance with 
alemtuzumab was provided for one year in patients not el-
igible for allogeneic hematopoietic stem cell transplanta-
tion (allo-HSCT) (30 mg s.c. once a month in months 1–6, 
and another 30 mg in months 9 and 12). In the group of 
previously untreated patients analyzed per protocol, the 
response rate was 75%. Median progression-free surviv-
al for the entire patient population (13 treatment-naïve, 
5 FMCA-A in the second-line) in the intent-to-treat (ITT) 
analysis was 7.5 months, and in the analysis of actually 
treated patients (per protocol) 11.2 months. The authors 
highlighted that the side effects of chemotherapy made 
it impossible to maintain the appropriate intensity of the 
treatment with alemtuzumab, and therefore reduced the 
effectiveness of the therapy.
The administration of bendamustine in the first-line of 
treatment allows a response to be obtained only in 67% of 
patients, with a short response duration of 2–10 months 
[32]. Therefore, bendamustine is not recommended at 
this stage. It is worth noting however that the use of ben-
damustine is associated with relatively low toxicity. There-
fore, in a group of carefully selected patients with severe 
comorbidities or in the case of alemtuzumab intolerance, 
its use may be exceptionally considered.
In patients with an unsatisfactory response to alemtu-
zumab (persistent high tumor mass, persistent high number 
of leukemic cells), an increase in the frequency of alemtu-
zumab administration or the addition of a purine nucleo-
side analogue, most often fludarabine or pentostatin, may 
be considered [29, 33].
There is no data on maintenance treatment with 
alemtuzumab after completion of induction therapy con-
taining alemtuzumab, hence this treatment is not cur-
rently recommended. However, a study on the use of ro-
midepsin in maintenance therapy is currently ongoing 
(NCT02512497).
When using alemtuzumab, it is important to prevent 
Pneumocystis jiroveci and Herpesviridae (HSV, CMV) in-
fections. Regular CMV monitoring in the blood is essential, 
ideally by quantitative PCR testing. CMV reactivation may 
affect up to 50% of patients [29].
Currently, central nervous system involvement pro-
phylaxis is not recommended. There are no systematic re-
ports on the treatment of CNS involvement. According to 
the experts, it is necessary to use intrathecal cytostatics 
e.g. a three-drug protocol containing methotrexate, cytar-
abine, and a glucocorticosteroid or systemically adminis-
tered methotrexate in doses that ensure penetration into 
the CNS [15]. In a report by Alsawah et al. [34], the intra-
thecal administration of alemtuzumab was effective.
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It is worth mentioning that alemtuzumab is not avail-
able in Poland for hematological indications. According to 
the regulations of the Ministry of Health and Social Welfare, 
this drug is available only via target import. In addition to 
submitting the target import application, it is necessary to 
contact Clinigen to register, and then complete the form 
sent by the company. This can be done by telephone on 
+44 (0) 1283 494 340 (fax +44 (0) 1283 494 341) or by 
e-mail: customer.services@clinigengroup.com. The drug is 
delivered to the pharmacy by the Komtur company.
Consolidation treatment
Allo-HSCT used in the consolidation of the induction 
treatment is the recommended therapeutic procedure in 
younger patients in good general condition without signifi-
cant comorbidities. This means that this procedure can be 
performed only in 30–50% of patients [29].
In the first published study involving a large group of 
patients, Krishnan et al. [35] analyzed 28 patients, includ-
ing 13 treated with allo-HSCT and 15 undergoing autolo-
gous hematopoietic stem cell transplantation (auto-HSCT). 
All had previously received alemtuzumab. Comparison of 
the transplant results with the historical control group of 
patients who achieved complete remission after treat-
ment with alemtuzumab and survived at least 6 months 
showed increased OS from 20 months in the control group 
to 33 months in the allo-HSCT group, and to 48 months in 
the entire group of patients who underwent any hemato-
poietic stem cell transplantation. The authors did not ob-
serve any differences in OS between the patients under-
going allo- and auto-HSCT [35].
In a retrospective EMBT analysis of 41 patients trans-
planted before 2007, it was found that after allo-HSCT, 
3-year OS was 21% (95% CI: 7–34%) while 3-year re-
lapse-free survival was (RFS) 19% (95% CI: 6–31%). The 
3-year incidences of relapse (RI) and non-relapse mortality 
(NRM) were both 41%. Most relapses were observed in the 
first year after allo-HSCT. The use of total body irradiation 
(TBI) for conditioning as well as early transplantation (less 
than one year from diagnosis) were associated with longer 
relapse-free survival. It should be remembered, however, 
that patients in complete or partial remission constituted 
only 56% of the group, while patients previously treated with 
alemtuzumab made up 24% [36]. In the prospective EBMT 
analysis performed between 2007 and 2012, the results 
of elective transplantation were evaluated in 37 patients 
without T-PLL progression. In this group, 4-year progres-
sion-free survival was 30% (95% CI: 14–46), and 4-year 
OS was 42% (95% CI, 25–49). The 4-year RI and NRM were 
38% (95% CI: 22–55) and 32% (95% CI: 16–47), respec-
tively. In univariate analysis, only whole body irradiation at 
a dose of 6 Gy or higher was associated with a lower risk of 
relapse, and time from diagnosis to allo-HSCT of less than 
12 months with lower non-relapse mortality [37].
More data on the efficacy of allotransplantation of he-
matopoietic cells was published in a French study involv-
ing 27 patients. In this group, 3-year OS was 36% (95% CI: 
17–54%), while the 3-year PFS was 26% (95% CI: 14–45%). 
Relapses were mainly observed during the first 24 months, 
with a median time to relapse of 11.7 months. The 3-year 
NRM was 31%. Patients with response to the induction 
therapy constituted the majority of the group (89%) [38].
To summarize the data on allo-HSCT in patients with 
T-PLL, recently a gradual improvement in the prognosis of 
these patients has been observed. However, long-term sur-
vival is achieved in less than 50% of patients. Treatment 
failure can be caused by both relapse of the disease and 
non-relapse mortality.
Effective consolidation therapy in patients not eligible 
for allo-HSCT has not yet been identified. For this reason, 
consolidation and maintenance treatments are not used 
in this group of patients.
Treatment of relapse
Relapse is expected in all T-PLL patients who have not 
undergone allo-HSCT, as well as in a high percentage of 
transplanted patients. Treatment options in relapse are 
very limited. Provided that alemtuzumab has not been 
used before, alemtuzumab therapy seems justified in 
relapse. This option can also be used in patients with late 
relapse, i.e. after at least 6 months of remission. In these 
cases, it is necessary to confirm CD52 expression on the 
surface of the T-PLL cells. It should be remembered that 
CD52 expression should not be evaluated in bone mar-
row immunohistochemistry due to the high rate of false 
negative results [29]. In patients for whom alemtuzumab 
seems unjustified, purine nucleoside analogues or pos-
sibly bendamustine, optimally at a dose of 120 mg/m2 
for the first two days of the 21-day cycle, should be ad-
ministered [15, 32]. 
New therapeutic possibilities
Due to constantly improving understanding of the patho-
genesis of T-PLL and the ability to identify potential molec-
ular targets, it seems that targeted drugs such as histone 
deacetylase inhibitors (HDACs), EZH1/2 inhibitors, and 
p53-reactivating drugs, e.g. MDM2 inhibitors, JAK/STAT 
pathway inhibitors, CDK inhibitors, PI3K inhibitors (co-
panlisib, duvelisib) [9–11, 39, 40], or venetoclax could be 
effective in the treatment of relapse.
Venetoclax, HDAC inhibitors, and JAK inhibitors have al-
ready been used in patients with refractory T-PLL. The use 
of venetoclax in two patients with refractory T-PLL allowed 
for partial remission in both [41] and combined treatment 
with pentostatin and venetoclax resulted in a complete re-
mission lasting 10 months [16]. In patients refractory to 
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alemtuzumab monotherapy, the combination of HDAC with 
cladribine and alemtuzumab was effective [42], whereas 
treatment with JAK inhibitors (tofacitinib, ruxolitinib) was 
associated with only moderate efficacy [43].
Based on the results of in vitro studies, it seems that 
combined treatment with bendamustine and HDAC inhib-
itors including tinostamustine, which is a compound re-
sulting from the combination of bendamustine and vori-
nostat, could also be effective [44]. Tinostamustine is 
currently being tested in clinical trials (NCT02576496). 
Similarly, the combination of venetoclax and ibrutinib 
that sensitizes T-PLL cells to venetoclax via ITK pathway 
(IL-2 inducible T cell kinase), could improve the effica-
cy of the treatment [45]. A phase II trial evaluating such 
a combination in alemtuzumab-refractory patients was 
started in 2019 (NCT03873493). Disappointing results 
in in vitro studies were obtained for poly-ADP-ribose poly-
merase (PARP) inhibitors [10], despite significant premis-
es suggesting their effectiveness in this indication [46].
After the initial success of chimeric antigen recep-
tor T-leukocytes (CAR-T) in cancer treatment, the use of 
immunotherapy in T-PLL is broadly discussed. Unlike in 
B-cell lymphoid neoplasms, it is difficult to identify the 
target for CAR-T cells in T-PLL. The use of CAR-T against 
an antigen commonly found on T lymphocytes is unac-
ceptable, as this would lead to aplasia of T lymphocytes 
and, consequently, severe immune disorders. According 
to this concept, Maciocia et al. [47] produced CAR-T cells 
Table III. Definition of response after treatment according to T-cell Prolymphocytic Leukemia International Study Group (TPLL-ISG) [8]
Groups Complete remission 
(CR) 




Progressive disease  
(PD) 
All criteria met At least 2 criteria from group 
A and at least  
1 criterion from group B met***
All criteria met At least 1 criterion from 
group A or B met
GROUP A
Lymph node size* In the long-axis  
diameter <1.0 cm 
SLD reduction by ≥30% A reduction of less 
than 30% or an 
increase of no more 
than 20%
SLD increase by 
>20%*****
Spleen dimension <13 cm A reduction of ≥50%  
in vertical length beyond  
normal from baseline
A change of no more 
than 49% beyond  
normal from baseline
An increase of ≥50% in 




Absent Any Any Any
Peripheral blood  
lymphocytes count
<4 ×109/L ≤30 ×109/L and a decrease  
of ≥50% from baseline
>30 ×109/L or no 
more than 49%  
change from baseline
An increase of ≥50% from 
baseline
Bone marrow T-PLL cells <5% of 
mononuclear cells
Any result other than complete 
remission
Any Any
Involvement of any 
specific site**
None Any Any Any
GROUP B
Platelet count ≥100 ×109/L  
(untransfused)
≥100 ×109/L or ≥50% increase 
from baseline  
(untransfused)
No more than 49% 
change from baseline




≥11 g/dL  
(untransfused;  
independant of ESAs)
≥11 g/dL or ≥50% increase 
from baseline (untransfused; 
independant of ESAs)
<11 g/dL or <50% 
change from baseline 
or less than 2 g/dL 
change
≥2 g/dL decrease  
from baseline




≥1.5 ×109/L or ≥50% increase 
from baseline  
(independant of granulocyte 
colony stimulating factors)
Change by no more 
than 49%
A decrease of ≥50% from 
baseline
*Assessed for lymph nodes with a long axis diameter ≥1.5 cm before the initiation of treatment; assessment should be performed using computed tomography (CT) or magnetic resonance imaging (MRI); 
**pleural effusion, peritoneal effusion, infiltrates in the skin, central nervous system; ***if initially only one parameter was incorrect, only that one parameter needs to be improved; ****stable disease is 
diagnosed only after it persists for at least 3 months; *****for small lymph nodes <1.5 cm it is necessary to increase the diameters by 5 mm and the long-axis diameter to 1.5 cm; SLD — sum of the long- 
-axis diameters of the 3 target lesions ; ESAs — erythropoiesis stimulating agents
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directed against TRBC1 (TCR beta-chain constant 1), that 
selectively targeted T-PLL cells expressing this domain, 
and saved healthy T-cells with the TRBC2 domain. The 
experiments were performed both in vitro and in an an-
imal model. There is no data on the use of CAR-T in this 
indication in humans.
Treatment response evaluation
Response to treatment should be assessed according to 
the criteria proposed by the TPLL-ISG [8]. Due to the fact 
that different treatments have different expected response 
durations, the timing of the response assessment should 
be individualized for each patient and the type of treatment 
being administered.
The response should be evaluated based on two groups 
of parameters: group A for general symptoms and parame-
ters that are a direct indicator of tumor mass, and group B 
for the effect of T-PLL cells on hematopoietic cells. Criteria 
for the evaluation of imaging diagnostics in T-PLL have not 
been developed so far. Until such criteria are developed, 
the iwCLL criteria for chronic lymphocytic leukemia [48] or 
the Lugano criteria for lymphomas [49] can be used. Due 
to the simplicity of the assessment, the TPLL-ISG proposes 
the use of the RECIL criteria [50] in which, unlike the RE-
CIST criteria, only three target lesions are assessed, sum-
ming up their length in one dimension.
Response criteria are presented in Table III. 
In complete remission (CR), it is necessary to exclude 
splenomegaly and hepatomegaly by physical examination. 
If all criteria for complete remission from group A are met, 
and at least one criterion from group B is not met, complete 
remission with incomplete hematological recovery (CRi) is 
diagnosed. The diagnosis of CR and CRi requires confir-
matory bone marrow examination, including aspirate and 
histopathological examination. However, this examination, 
similarly to imaging diagnostics, should be performed only 
after achieving the response, as evaluated in the complete 
blood count. For CR, it is not necessary to exclude minimal 
residual disease (MRD).
Stable disease is diagnosed in patients who do not 
achieve at least partial remission and who do not show 
evidence of disease progression, as long as it persists for 
at least three months.
In T-PLL progression, the deterioration of peripheral 
blood count parameters must directly result from bone 
marrow involvement by the T-PLL infiltration. It is necessary 
to exclude the toxicity of the drugs, as well as autoimmune 
cytopenia. In uncertain cases, bone marrow examination 
may be necessary.
The objective response rate (ORR) is defined as the per-
centage of patients achieving one of the following respons-
es: CR, CRi, or partial remission (PR). In turn, the best objec-
tive response is defined as the best response maintained 
for at least four weeks with continuous treatment, and for 
at least eight weeks with intermittent treatment.
The authors of the recommendations advocate the in-
troduction of the term ‘disease control rate’, which would 
include CR, CRi, partial remission (PR) and stable disease 
(SD), as well as the term ‘disease control time’.
TPLL-ISG recommendations [8] also define the end-
points that should be assessed for T-PLL, such as: PFS, 
event-free survival (EFS), time to next treatment, OS, 
relapse, refractory disease and treatment failure, and fi-
nally MRD.
Follow-up after treatment  
and obtaining remission
After the treatment is completed and remission is obtained, 
follow-up visits should take place every 4–6 weeks and 
should include physical examination, CBC, and biochem-
ical tests.
Conclusions
T-cell prolymphocytic leukemia is a very rare disease of the 
lymphoid system with an unfavorable prognosis. Despite 
the increasing efficacy of the therapeutic approaches, 
long-term disease control can only be achieved with allo-
geneic hematopoietic stem cell transplantation, and only 
in selected patients. Current reports show that the results 
of transplantation are significantly improved, as long as 
the patients referred for transplantation are in complete 
remission after alemtuzumab treatment. Undoubtedly, it is 
necessary to seek new therapeutic methods, especially for 
patients not eligible for allo-HSCT or in relapse. Due to the 
rarity of the disease, multi-center collaboration is necessary.
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